MX2022005864A - Formas cristalinas de un inhibidor de magl. - Google Patents

Formas cristalinas de un inhibidor de magl.

Info

Publication number
MX2022005864A
MX2022005864A MX2022005864A MX2022005864A MX2022005864A MX 2022005864 A MX2022005864 A MX 2022005864A MX 2022005864 A MX2022005864 A MX 2022005864A MX 2022005864 A MX2022005864 A MX 2022005864A MX 2022005864 A MX2022005864 A MX 2022005864A
Authority
MX
Mexico
Prior art keywords
crystalline forms
magl inhibitor
magl
inhibitor
hexafluoropropan
Prior art date
Application number
MX2022005864A
Other languages
English (en)
Inventor
De Diego Heidi Lopez
Daniel J Buzard
Nicole S White
Cheryl A Grice
Frans Dennis Therkelsen
Michael B Shaghafi
Ida Marie Brodsgaard Knudsen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MX2022005864A publication Critical patent/MX2022005864A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

En la presente se describen nuevas formas cristalinas del inhibidor de MAGL ácido 2-(2-((4-(((1,1,1,3,3,3,-hexafluoropropan- 2-il)oxi)carbonil)piperazin-1-il)metil)-5-(trifluorometil)fenoxi) -2-metilpropanoico, o una sal farmacéuticamente aceptable del mismo.
MX2022005864A 2019-11-15 2020-11-12 Formas cristalinas de un inhibidor de magl. MX2022005864A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962936126P 2019-11-15 2019-11-15
PCT/US2020/060261 WO2021097107A1 (en) 2019-11-15 2020-11-12 Crystalline forms of a magl inhibitor

Publications (1)

Publication Number Publication Date
MX2022005864A true MX2022005864A (es) 2022-08-16

Family

ID=75908549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005864A MX2022005864A (es) 2019-11-15 2020-11-12 Formas cristalinas de un inhibidor de magl.

Country Status (12)

Country Link
US (1) US20210147367A1 (es)
EP (1) EP4058431A4 (es)
JP (1) JP2023502048A (es)
KR (1) KR20220101095A (es)
CN (1) CN114761382A (es)
AR (1) AR120462A1 (es)
AU (1) AU2020383502A1 (es)
BR (1) BR112021013917A2 (es)
CA (1) CA3159391A1 (es)
IL (1) IL292847A (es)
MX (1) MX2022005864A (es)
WO (1) WO2021097107A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028085B1 (ru) * 2012-01-06 2017-10-31 Эбайд Терапьютикс, Инк. Карбаматные соединения и их применение
WO2015179559A2 (en) * 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2016014975A2 (en) * 2014-07-25 2016-01-28 Northeastern University Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
US9771341B2 (en) * 2015-03-18 2017-09-26 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
JP7042804B2 (ja) * 2016-09-19 2022-03-28 ルンドベック ラ ホーヤ リサーチ センター，インク． ピペラジンカルバメート、及びその製造と使用の方法
JOP20190106A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190109B1 (ar) * 2016-11-16 2022-09-15 H Lundbeck As أشكال بلورية من مثبط أحادي أسيل جليسرول ليباز (magl)
CN112088001A (zh) * 2018-05-15 2020-12-15 隆德贝克拉荷亚研究中心有限公司 Magl抑制剂
MX2021008865A (es) * 2019-01-25 2021-10-26 H Lundbeck As Inhibidores de magl para usarse para tratar enfermedades antecedentes.

Also Published As

Publication number Publication date
US20210147367A1 (en) 2021-05-20
EP4058431A4 (en) 2023-11-15
WO2021097107A1 (en) 2021-05-20
BR112021013917A2 (pt) 2022-05-24
JP2023502048A (ja) 2023-01-20
AR120462A1 (es) 2022-02-16
IL292847A (en) 2022-07-01
KR20220101095A (ko) 2022-07-19
CN114761382A (zh) 2022-07-15
CA3159391A1 (en) 2021-05-20
EP4058431A1 (en) 2022-09-21
AU2020383502A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
CO2020000193A2 (es) Compuestos antiproliferativos y métodos para utilizarlos
PH12019501068A1 (en) Crystalline forms of a magl inhibitor
CL2017000705A1 (es) Nuevos compuestos
AR105238A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
RS54192B1 (en) DERIVATIVES OF HYDROXAMIC ACIDS
MD3573983T2 (ro) N-[4-fluoro-5-[[(2S,4S)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamidă în calitate de inhibitor OGA
PE20191146A1 (es) Inhibidores de magl
EP3796909A4 (en) TREATMENT OF MULTIPLE MYELoma AND USE OF BIOMARKERS FOR 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)-PIPERAZINE -1-YL)-3-FLUOROBENZONITRILE
MX2023009701A (es) Formas solidas de 2-(3,5-dicloro-4-( (5-isopropil-6-oxo -1,6-dihidropiridazin-3-il) oxi) fenil)-3,5-dioxo -2,3,4,5-tetrahidro -1,2,4-triazina-6-carbonitrilo.
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
DK2164492T3 (da) Trans-4-{2-[4-(2,3-dichlorphenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoylcyclohexylamin til behandling af skizofreni
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
TN2016000491A1 (en) Carboxamide derivatives.
ZA202211124B (en) Synthesis of a monoacylglycerol lipase inhibitor
EP3735243A4 (en) ISOTOPOLOGISTS OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE
MX2019001007A (es) Uso novedoso de nectinib y una sal farmaceuticamente aceptable del mismo en el tratamiento contra enfermedades.
DE602006015291D1 (de) Hiv-inhibierende 2-(4-cyanophenyl)-6-hydroxylaminopyrimidine
MX2021000468A (es) Inhibidores de la histona desacetilasa.
SG11202107439XA (en) Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
MX2022005864A (es) Formas cristalinas de un inhibidor de magl.
AR116951A1 (es) Sales cristalinas de un inhibidor de calicreína plasmática
CR20210334A (es) FORMAS POLIMÓRFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFb
MX2020008610A (es) Agente terapeutico para carcinoma hepatocelular.
MX2021007258A (es) Composiciones de esparsentan amorfas.
AR116428A1 (es) Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo